Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share Price

Price 11,822.00p on 09-09-2026 at 09:57:27
Change -54.00p -0.45%
Buy 11,822.00p
Sell 11,818.00p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Buy 79.00 at 11,822.00p
Day's Volume: 390,111
Last Close: 11,876.00p
Open: 11,850.00p
ISIN: GB0009895292
Day's Range 11,796.00p - 11,996.00p
52wk Range: 10,784.00p - 15,730.00p
Market Capitalisation: £183.35b
VWAP: 11,868.43687p
Shares in Issue: 1.55b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Lower Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Astrazeneca (AZN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 79 11,822.00p Automatic Execution
 10:57:15 - 09-Sep-26
Buy* 31 11,822.00p Automatic Execution
 10:57:15 - 09-Sep-26
Buy* 10 11,818.00p Automatic Execution
 10:56:57 - 09-Sep-26
Buy* 11 11,816.00p Automatic Execution
 10:56:56 - 09-Sep-26
Buy* 3 11,816.396p Ordinary
 10:56:51 - 09-Sep-26
Buy* 7,572 11,819.82p Ordinary
 10:56:47 - 09-Sep-26
Sell* 106 11,816.00p Automatic Execution
 10:56:43 - 09-Sep-26
Buy* 9 11,816.00p Automatic Execution
 10:56:43 - 09-Sep-26
Sell* 8 11,812.00p SI Trade
 10:56:30 - 09-Sep-26
Buy* 49 11,814.00p Automatic Execution
 10:56:26 - 09-Sep-26
See more Astrazeneca trades

Astrazeneca (AZN) Share Price History

Time period:
to
Date Open High Low Close Volume
8th Sep 2026 (Tue) 11,958.00 12,122.00 11,852.00 11,876.00 2,301,862
7th Sep 2026 (Mon) 11,986.00 12,210.00 11,952.00 12,042.00 1,975,838
4th Sep 2026 (Fri) 12,146.00 12,206.00 11,986.00 12,006.00 2,248,244
3rd Sep 2026 (Thu) 12,066.00 12,290.00 12,018.00 12,146.00 2,393,791
2nd Sep 2026 (Wed) 12,032.00 12,194.00 11,846.00 11,976.00 2,765,667
1st Sep 2026 (Tue) 11,650.00 12,132.00 11,650.00 11,962.00 2,914,001
31st Aug 2026 (Mon) 11,970.00 11,970.00 11,970.00 11,970.00 0
28th Aug 2026 (Fri) 12,200.00 12,200.00 11,960.00 11,970.00 3,627,372
27th Aug 2026 (Thu) 12,194.00 12,236.00 12,066.00 12,114.00 3,580,331
26th Aug 2026 (Wed) 12,450.00 12,462.00 12,214.00 12,234.00 2,783,597
25th Aug 2026 (Tue) 12,220.00 12,476.00 12,124.00 12,476.00 2,035,709
24th Aug 2026 (Mon) 12,182.00 12,204.00 12,016.00 12,110.00 1,791,143
21st Aug 2026 (Fri) 11,926.00 12,242.00 11,926.00 12,240.00 2,343,868
20th Aug 2026 (Thu) 12,162.00 12,162.00 11,844.00 12,088.00 3,148,662
19th Aug 2026 (Wed) 11,858.00 12,140.00 11,834.00 12,050.00 3,132,856
18th Aug 2026 (Tue) 11,558.00 11,846.00 11,548.00 11,806.00 3,193,800
17th Aug 2026 (Mon) 11,550.00 11,690.00 11,488.00 11,560.00 3,230,472
14th Aug 2026 (Fri) 11,610.00 11,650.00 11,404.00 11,460.00 4,271,602
13th Aug 2026 (Thu) 11,706.00 11,746.00 11,604.00 11,708.00 3,381,662
12th Aug 2026 (Wed) 11,786.00 11,796.00 11,612.00 11,702.00 1,676,955
11th Aug 2026 (Tue) 11,980.00 12,056.00 11,840.00 11,844.00 2,712,882
10th Aug 2026 (Mon) 12,030.00 12,060.00 11,856.00 11,990.00 3,814,704
See more Astrazeneca price history

Astrazeneca (AZN) Regulatory News

Date Source Headline
8th Sep 2026 2:00 pm RNS Imfinzi+Imdelltra improved OS in small cell lung
7th Sep 2026 7:00 am RNS Etcamah approved in the US for HR+ breast cancer
1st Sep 2026 3:05 pm RNS Admission of Further Securities to Trading
1st Sep 2026 3:00 pm RNS Total Voting Rights
1st Sep 2026 11:00 am RNS Admission to Trading - €2.55 billion bond offering
1st Sep 2026 7:30 am RNS Enhertu approved in EU for 1L HER2-positive mBC
1st Sep 2026 7:10 am RNS Directorate change
1st Sep 2026 7:05 am RNS AstraZeneca completes agreement for Zegfrovy
1st Sep 2026 7:00 am RNS Tagrisso + Orpathys improved PFS in 1L EGFRm lung
27th Aug 2026 7:00 am RNS Tezspire CROSSING trial met primary endpoints
See more Astrazeneca regulatory news

Astrazeneca (AZN) Share News

LONDON BROKER RATINGS: RBC prefers Astra to GSK; HSBC cuts Burberry

9th Sep 2026 09:04

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More

AstraZeneca hails tozorakimab licence application approval in US

8th Sep 2026 14:21

(Alliance News) - AstraZeneca PLC on Tuesday said its biologics licence application for tozorakimab in the US was accepted under priority review. Read More

LONDON BROKER RATINGS: Jefferies raises Autotrader and Rightmove

8th Sep 2026 09:08

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More

IN BRIEF: AstraZeneca wins US nod for Etcamah breast cancer combo

7th Sep 2026 01:08

AstraZeneca PLC - Cambridge, England-based pharmaceuticals firm - Welcomes the US Food & Drug Administration's accelerated approval of Etcamah for use alongside a cyclin‑dependent kinase 4 and 6 inhibitor, a type of medicine that slows cancer cell growth, in adults with advanced hormone‑driven breast cancer. Says Etcamah, which blocks the effect of estrogen on tumour cells, is cleared for patients who develop a mutation in the estrogen receptor 1 gene, a change that can make standard hormone treatment stop working. AstraZeneca says the decision is supported by Serena-6 phase three trial showing the combination keeps the disease from worsening for longer than current first‑line therapy. The firm adds that safety findings are in line with what is already known about the medicines used. Etcamah is also approved in more than 30 countries. Read More

IN BRIEF: Hutchmed "thrilled" by positive phase 3 trial results

1st Sep 2026 13:37

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Announces "positive high-level results" from the Sanovo China phase 3 trial of Orpathys plus Tagrisso in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer, whose tumours harbour epidermal growth factor receptor mutation and MET overexpression. Orpathys, or savolitinib, combined with Tagrisso or osimertinib, showed "a statistically significant and highly clinically meaningful improvement in progression-free survival" in the high MET and intention-to-treat patient populations, compared with Tagrisso alone. Hutchmed adds that "the combination also demonstrated a very encouraging clinical benefit in [the secondary endpoint of] overall survival" in both populations. Hutchmed is jointly developing Orpathys with AstraZeneca, which is also commercialising the treatment. Read More

See more Astrazeneca news
FTSE 100 Latest
Value10,756.98
Change-54.68

Login to your account

Forgot Password?

Not Registered